Biaryl substituted hydantoin compounds as TACE inhibitors.
Yu, W., Tong, L., Kim, S.H., Wong, M.K., Chen, L., Yang, D.Y., Shankar, B.B., Lavey, B.J., Zhou, G., Kosinski, A., Rizvi, R., Li, D., Feltz, R.J., Piwinski, J.J., Rosner, K.E., Shih, N.Y., Siddiqui, M.A., Guo, Z., Orth, P., Shah, H., Sun, J., Umland, S., Lundell, D.J., Niu, X., Kozlowski, J.A.(2010) Bioorg Med Chem Lett 20: 5286-5289
- PubMed: 20663669 
- DOI: https://doi.org/10.1016/j.bmcl.2010.06.134
- Primary Citation of Related Structures:  
3LE9, 3LEA - PubMed Abstract: 
We disclose further optimization of hydantoin TNF-alpha convertase enzyme (TACE) inhibitors. SAR with respect to the non-prime region of TACE active site was explored. A series of biaryl substituted hydantoin compounds was shown to have sub-nanomolar K(i), good rat PK, and good selectivity versus MMP-1, -2, -3, -7, -9, and -13.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA. wensheng.yu@merck.com